Intel Corp vs Smith & Nephew plc — how do they compare? Intel Corp trades at $99.83 (market cap $491.89B), while Smith & Nephew plc trades at $30.05 (market cap $12.50B). The key difference: Intel Corp is far larger — about 39.4× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.64%). Which is the better fit depends on your goals.
| INTC | SNN | |
|---|---|---|
Market Cap | $491.89B | $12.50B |
Volume | 43,552,012 | — |
Sector | Technology | Health |
52-Week High | $140.94 | $38.70 |
52-Week Low | $21.81 | $28.73 |
Enterprise Value | $512.70B | $15.53B |
Dividend Yield | 2.24% | 2.64% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SNN trades at $30.11, up 1.41% in the last session. Technical indicators are bearish, with moving averages signaling a downtrend. Fundamentally, the company reported Q2 2026 revenue growth of 1.6% but cut its full-year outlook to 4% from 6% due to weakness in U.S. Orthopaedics and Advanced Wound Bioactives (MarketBeat, 2026-08-09). Recent product launches include the LYNX COBLATION Wand and CORI XT robotics platform, supporting innovation in medical technology.
The outlook is mixed: strong profitability margins and recent earnings beats offer support, but lowered guidance and bearish technicals pose near-term headwinds. Risks include execution challenges in key markets, while analyst consensus leans Hold, reflecting cautious optimism amid growth uncertainties.
Trailing returns across standard periods
Latest headlines on both assets
Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.
Read more on INTC →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →